MedTwenty Indices and trackers are editorial indicators and business information. They are not investment, financial, legal or medical advice, and not a regulated benchmark.
Summary
Sequencing-led precision medicine company combining clinical genomic profiling with a large real-world oncology data asset. Now the acquirer of Personalis and a direct competitor to Foundation Medicine in comprehensive genomic profiling.
Finances
Not published (small company accounts)
Timeline
No verified timeline entries yet.